Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dapagliflozin

dapagliflozin

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dapagliflozin

89 trials tracked of dapagliflozin: 69 in phase 3 or 4 and 30 with published results. The most-cited published study has 645 citations.

89Trials tracked
69Phase 3 & 4
0Recruiting
30With published results
Phase distribution
Phase 4 23 Phase 3 46 Phase 2 13 Phase 1 4 Other / NA 3
  1. Phase 3 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Completed · 645 cited
  2. Phase 4 Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Completed · 425 cited
  3. Phase 3 Add-on to Thiazolidinedione (TZD) Failures Completed · 402 cited
  4. Phase 3 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Completed · 389 cited
  5. Phase 3 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed · 361 cited
  6. Phase 3 An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets Completed · 313 cited
Show 44 more trials
  1. Phase 3 Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. Completed · 267 cited
  2. Phase 4 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus Completed · 246 cited
  3. Phase 4 An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Completed · 189 cited
  4. Phase 3 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 149 cited
  5. Phase 3 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 85 cited
  6. Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years Completed · 84 cited
  7. Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 77 cited
  8. Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 77 cited
  9. Phase 4 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Completed · 73 cited
  10. Phase 3 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Completed · 69 cited
  11. Phase 4 Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. Completed · 59 cited
  12. Phase 3 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Completed · 56 cited
  13. Phase 3 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction Completed · 53 cited
  14. Phase 3 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Completed · 53 cited
  15. Phase 4 Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 Completed · 42 cited
  16. Phase 3 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Completed · 34 cited
  17. Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old Completed · 34 cited
  18. Phase 3 Phase III Insulin Add-On Asia Regional Program - ST Completed · 26 cited
  19. Phase 3 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure Completed · 25 cited
  20. Phase 4 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed · 15 cited
  21. Phase 3 A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed · 13 cited
  22. Phase 3 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Completed · 13 cited
  23. Phase 4 Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Completed · 10 cited
  24. Phase 3 A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease Completed · 6 cited
  25. Phase 4 Vildagliptin Versus Dapagliflozin on Glucagon Completed
  26. Phase 4 Foxiga Korea Local Phase 4 Study Completed
  27. Phase 4 A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients Completed
  28. Phase 4 Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) Completed
  29. Phase 4 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed
  30. Phase 4 Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension Completed
  31. Phase 4 Dapagliflozin Effects on Epicardial Fat Completed
  32. Phase 4 Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes Completed
  33. Phase 4 Dapagliflozin at Discharge on Hospital Heart Failure Readmission Completed
  34. Phase 4 Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects Completed
  35. Phase 4 Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Completed
  36. Phase 4 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration Completed
  37. Phase 4 Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation Completed
  38. Phase 4 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Completed
  39. Phase 4 Anti-Diabetic Medications to Fight PD and LBD Completed
  40. Phase 3 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise Completed
  41. Phase 3 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed
  42. Phase 3 Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Completed
  43. Phase 3 A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes Completed
  44. Phase 3 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets for Type 2 Diabetes and Related Risks
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets for Type 2 Diabetes and Related Risks FDA approves a new once-daily pill for type 2 diabetes that may also help protect the heart and kidneys
The FDA has approved dapagliflozin and metformin hydrochloride extended-release tablets as an adjunct to diet and exercise to improve glycem…
A new once-daily pill for type 2 diabetes may protect the heart and kidneys from serious problems like heart attacks and worsening kidney di…
FDA Apr 10, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes FDA approves a diabetes pill that also helps protect the heart from failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction FDA approves a new diabetes pill that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Apr 9, 2026
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes FDA approves a diabetes drug that also helps lower the risk of heart failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Apr 9, 2026
FDA Approves Dapagliflozin for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart from failure
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established ca…
FDA approves a diabetes pill that lowers blood sugar and reduces heart failure hospitalization for adults with type 2 diabetes and heart ris…
FDA Apr 9, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk in Adults with Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk in Adults with Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug now protects the heart by lowering hospitalization risks for adults with type 2 diabetes and existing heart disease.
FDA Apr 9, 2026
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
Cardiology Meta-analysis
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
Apr 6, 2026
Phase 4 trial compares pioglitazone versus dapagliflozin add-on in type 2 diabetes
Diabetes & Endocrinology Phase IV
Phase 4 trial compares pioglitazone versus dapagliflozin add-on in type 2 diabetes Trial compares two diabetes drug combinations but results are not yet available
A phase 4 randomized controlled trial in South Korea enrolled 133 participants with type 2 diabetes inadequately controlled by DPP-4 inhibit…
A completed trial in South Korea compared two three-drug combinations for type 2 diabetes, but results on blood sugar control are not yet av…
CT.gov Apr 3, 2026